title: Target selection issues in drug discovery and development.
abstract: Targets for cancer treatments have been proposed which address oncogenes mutated in tumors (pathogenic targets). Yet additional opportunities may come from molecules expressed in the tissue of origin (ontogenic); allow drug handling (pharmacological) or address the tumor microenvironment. The key is to define an assay that defines a therapeutic index which can be achieved in modulated target function.
authors.affiliation: Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD, USA. esausville@umm.edu
authors.forename: E A
authors.initials: EA
authors.lastname: Sausville
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005544:Forecasting; D018390:Gene Targeting; D015894:Genome, Human; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D012680:Sensitivity and Specificity; D014481:United States
chemical_list: D000970:Antineoplastic Agents